New hope for tough melanomas: targeted drug shows promise in early trial

NCT ID NCT03420508

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Feb 05, 2026 · Last updated May 08, 2026 · Updated 11 times

Summary

This study tests an experimental drug called ensartinib in people with advanced melanoma that has a specific genetic abnormality (ALK alteration). The goal is to see if the drug can shrink tumors or keep them stable for at least 24 weeks. Participants must have already tried other standard treatments, including immunotherapy. The trial is currently active but no longer recruiting new participants.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Memorial Sloan Kettering Bergen

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Memorial Sloan Kettering Monmouth

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Westchester

Harrison, New York, 10604, United States

Conditions

Explore the condition pages connected to this study.

MELANOMA